Who
John Canan
Director
Company insider
Files Form 4 as: Director, Terex; Director, REV Group; Director, Grace Therapeutics; Sr.V-P Finc-Global Controller, Merck & Company; Senior V-P, Controller, Merck Sharp & Dohme.
In numbers
- Trades disclosed
- 112
- Buys
- 1
- Sells
- 2
- Bought
- $81K
- Sold
- $1.9M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 15 Jan 2007
- Last trade
- 2 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Feb 2026filed 4 Feb 2026 | TEX TerexMachinery | SEC FORM 4 Code A | —62,076 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TEX TerexMachinery | SEC FORM 4 Code A | —2,380 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TEX TerexMachinery | SEC FORM 4 Code A | —62,076 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TEX TerexMachinery | SEC FORM 4 Code A | —2,380 at $0.00 | filing |
| 2 Feb 2026filed 2 Feb 2026 | REV GroupAutomobiles & EV | SEC FORM 4 Code D | —63,285 at $0.00 | filing |
| 2 Feb 2026filed 2 Feb 2026 | REV GroupAutomobiles & EV | SEC FORM 4 Code D | —2,105 at $0.00 | filing |
| 2 Feb 2026filed 2 Feb 2026 | REV Group | SEC FORM 4 Code D | —63,285 at $0.00 | filing |
| 2 Feb 2026filed 2 Feb 2026 | REV Group | SEC FORM 4 Code D | —2,105 at $0.00 | filing |
| 3 Dec 2025filed 5 Dec 2025 | REV Group | SEC FORM 4 Code A | —2,105 at $0.00 | filing |
| 5 Dec 2024filed 9 Dec 2024 | REV Group | SEC FORM 4 Code A | —3,611 at $0.00 | filing |
| 8 Dec 2023filed 12 Dec 2023 | REV Group | SEC FORM 4 Code A | —7,084 at $0.00 | filing |
| 8 Dec 2022filed 12 Dec 2022 | REV Group | SEC FORM 4 Code A | —7,960 at $0.00 | filing |
| 28 Sep 2022filed 30 Sep 2022 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 9 Dec 2021filed 13 Dec 2021 | REV Group | SEC FORM 4 Code A | —5,945 at $0.00 | filing |
| 12 Nov 2021filed 16 Nov 2021 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,100 at $0.00 | filing |
| 11 Dec 2020filed 15 Dec 2020 | REV Group | SEC FORM 4 Code A | —10,584 at $0.00 | filing |
| 18 Dec 2019filed 20 Dec 2019 | REV Group | SEC FORM 4 Code A | —7,797 at $0.00 | filing |
| 9 Jan 2019filed 11 Jan 2019 | REV Group | SEC FORM 4 Code A | —11,099 at $0.00 | filing |
| 25 Jun 2018filed 27 Jun 2018 | REV Group | SEC FORM 4 Bought | $71K4,440 at $16.04 | filing |
| 25 Jun 2018filed 27 Jun 2018 | REV Group | SEC FORM 4 Bought | $6,424400 at $16.06 | filing |
News
Moderna, Merck shares fall on eagerly anticipated cancer vaccine resultsMRK · biopharmadive.com · 22 Oct 2026Merck & Co., Inc. $MRK Stock Sold by Smith Chas P & Associates PA CpasMRK · dailypolitical.com · 22 Oct 2026Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder CancerMRK · rttnews.com · 21 Oct 2026
0 headlines in the last 90 days name John Canan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.